Company intelligence / Profile preview

Darmiyan

San Francisco/Berkeley/Redwood City, California, USdarmiyan.com ↗

Ownership: Private
Development stage: Commercial

Overview

Developed AI-powered brain imaging software that detects Alzheimer's disease years before symptoms using routine MRIs. The BrainSee Test provides a prognostic score (0-100) for dementia risk within five years with high accuracy[2][3].

Therapeutic areas: Neurology
Modalities: AI-driven diagnostic software
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

BrainSee

Commercial

Indications: Alzheimer's disease, Mild cognitive impairment

Partnerships

MCRA (regulatory strategy)VB LLC (investor)

Beyond the preview

Go deeper on Darmiyan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Darmiyan.

Explore the full profile